Radical endoscopic thyroidectomy (ET) offers superior cosmetic outcomes and enhanced visibility of the surgical field compared to open surgery. However, the thyroid's unique physiological functions and intricate surrounding anatomy may result in various surgical complications. Mixed reality (MR), a real-time holographic visualization technology, enables the creation of highly realistic 3D models in the real world and facilitates multiple human-computer interactions. MR can be utilized for both preoperative evaluation and intraoperative navigation. First, semi-automatic 3D reconstruction of the neck from enhanced computed tomography images is performed using 3Dslicer. Next, the 3D model is imported into Unity3D to create a virtual hologram that can be displayed on an MR helmet-mounted display (HMD). During surgery, surgeons can wear the MR HMD to locate lesions and surrounding anatomy through the virtual hologram. In this study, patients requiring radical ET were randomly assigned to either the experimental group or the control group. Surgeons performed MR-assisted radical ET in the experimental group. A comparative analysis of surgical outcomes and the results of scales was conducted. This study successfully developed the neck 3D model and the virtual hologram. According to the NASA Task Load Index Scale, the experimental group exhibited significantly higher scores in 'Own Performance' and lower scores in 'Effort' compared to the control group (p = 0.002). Additionally, on the Likert Subjective Evaluation Scale, the mean scores for all questions exceeded 3. Although the incidence of surgical complications was lower in the experimental group than in the control group, the differences in surgical outcomes were not statistically significant.MR is beneficial for enhancing performance and alleviating the burden of surgeons during the perioperative period. Furthermore, MR has demonstrated the potential to enhance the safety of ET. Therefore, it is essential to further investigate the surgical applications of MR.
Background: Gastric cancer (GC) progression entails profound epithelial-stromal remodeling, yet how epithelial metabolic programs are linked to myeloid-dominated immune exclusion and prognostic risk remains unclear. This study aimed to integrate single-cell RNA sequencing (scRNA-seq) and bulk transcriptomic analyses to characterize a lactate-myeloid-related risk axis in GC. Methods: We integrated six scRNA-seq datasets comprising 116 samples and 355,091 cells spanning paratumor (PT), chronic atrophic gastritis (CAG), moderate intestinal metaplasia (MIM), severe intestinal metaplasia (SIM), early gastric cancer (EGC), and advanced gastric cancer (AGC), and coupled them to bulk cohorts. Epithelial and myeloid states, pseudotime trajectories, ligand-receptor programs, and pathway activities were analyzed. A 19-gene prognostic model anchored on SLC16A3/MCT4 co-expression and macrophage immunoregulatory modules was developed in The Cancer Genome Atlas stomach adenocarcinoma (TCGA-STAD) cohort and externally validated in GSE84437. Mutation burden, tumor immune dysfunction and exclusion (TIDE), and expression-based drug-response predictions were further evaluated. SLC16A3 expression was validated by immunohistochemistry (IHC) in an independent clinical cohort. Results: The integrated atlas showed immune contraction with epithelial expansion in premalignant lesions, followed by enrichment of aberrant epithelium and myeloid lineages in EGC/AGC. Within epithelium, a late-pseudotime SLC16A3+ lactate-export program increased with progression and was associated with extracellular matrix (ECM) remodeling, pro-angiogenic signaling, and myeloid-recruiting chemokines. IHC confirmed marked SLC16A3 enrichment within dense, cohesive neoplastic nests of Lauren intestinal and mixed subtypes. Myeloid decomposition revealed macrophage-centric expansion dominated by SPP1+ and APOE+ tumor-associated macrophage (TAM) states. The model-derived risk score stratified overall survival independently of clinical covariates. Low-risk tumors exhibited higher mutation counts and tumor mutational burden (TMB), whereas high-risk tumors were genomically quieter but TIDE-high. Expression-based analyses nominated differential drug-response patterns across risk groups, which require further validation. Conclusions: This study identifies an epithelial SLC16A3-associated lactate-myeloid transcriptional program linked to macrophage-rich immune exclusion and poor prognosis in GC. The 19-gene model provides a biologically interpretable framework for risk stratification, while the immune-evasion and drug-response findings should be considered hypothesis-generating and require prospective and functional validation.
Radical endoscopic thyroidectomy (ET) offers superior cosmetic outcomes and enhanced visibility of the surgical field compared to open surgery. However, the thyroid's unique physiological functions and intricate surrounding anatomy may result in various surgical complications. Mixed reality (MR), a real-time holographic visualization technology, enables the creation of highly realistic 3D models in the real world and facilitates multiple human-computer interactions. MR can be utilized for both preoperative evaluation and intraoperative navigation. First, semi-automatic 3D reconstruction of the neck from enhanced computed tomography images is performed using 3Dslicer. Next, the 3D model is imported into Unity3D to create a virtual hologram that can be displayed on an MR helmet-mounted display (HMD). During surgery, surgeons can wear the MR HMD to locate lesions and surrounding anatomy through the virtual hologram. In this study, patients requiring radical ET were randomly assigned to either the experimental group or the control group. Surgeons performed MR-assisted radical ET in the experimental group. A comparative analysis of surgical outcomes and the results of scales was conducted. This study successfully developed the neck 3D model and the virtual hologram. According to the NASA Task Load Index Scale, the experimental group exhibited significantly higher scores in 'Own Performance' and lower scores in 'Effort' compared to the control group (p = 0.002). Additionally, on the Likert Subjective Evaluation Scale, the mean scores for all questions exceeded 3. Although the incidence of surgical complications was lower in the experimental group than in the control group, the differences in surgical outcomes were not statistically significant.MR is beneficial for enhancing performance and alleviating the burden of surgeons during the perioperative period. Furthermore, MR has demonstrated the potential to enhance the safety of ET. Therefore, it is essential to further investigate the surgical applications of MR.
Triple-negative breast cancer (TNBC) is an aggressive subtype lacking effective targeted therapies. The molecular drivers of its progression and metabolic reprogramming remain unclear. Here, we identify cell division cycle-associated 4 (CDCA4) as a novel oncogenic driver in TNBC. Analysis of the TCGA-BRCA dataset, including 1085 breast cancer tissues and 112 normal tissues, showed that CDCA4 expression was significantly upregulated in breast cancer tissues. Subgroup analysis of TCGA-BRCA samples further showed higher CDCA4 expression (fold change = 1.707) in TNBC than in non-TNBC samples [TNBC, n = 116; non-TNBC, n = 984]. Survival analysis demonstrated that high CDCA4 expression was associated with poorer overall survival, with a hazard ratio of 1.54 (log-rank p = 0.0053). Functional assays demonstrated that CDCA4 knockdown suppresses proliferation, migration, invasion, and tumor growth in vitro and in vivo, whereas overexpression exerts opposite effects. RNA-sequencing revealed that CDCA4-regulated genes are enriched in lipid metabolism and mTOR signaling pathways. Mechanistically, CDCA4 depletion reduces intracellular lipids and the expression of lipogenic enzymes (FASN, ACC1). We show that CDCA4 activates mTOR and increases the nuclear active form of SREBP1, enhancing its promoter occupancy. Pharmacological mTOR inhibition reverses CDCA4-induced malignancy and metabolic alterations. Furthermore, Our findings suggest that SESN2 may contribute to CDCA4-mediated activation of mTOR signalling. SESN2 knockdown attenuates mTOR signaling and negates the pro-tumorigenic effects of CDCA4 overexpression. Collectively, these findings demonstrate that CDCA4 drives TNBC progression and lipid reprogramming via the SESN2/mTOR/SREBP1 axis, positioning CDCA4 as a potential prognostic biomarker and therapeutic target.